← Leaderboards
Georgia B Vogelsang
Johns Hopkins University
$948,829
Attributed
$948,829
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$948,829 · 2
By mechanism
K24$722,915 · 1
P01$225,914 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Elizabeth Marion Jaffee$29,780,612
- Nicole Baumgarth$23,275,831
- Martin G Pomper$38,517,075
- Arturo Casadevall$47,974,076
- Richard J Jones$17,555,212
Others in their field
Top investigators on “Neoplasm /Cancer Immunotherapy”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Charles A Coltman · Southwest Oncology Group$65,041,418
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Samuel A Wells · Duke University$32,148,803
- George Wilding · University Of Wisconsin Madison$22,104,400
Research focus
Neoplasm /Cancer ImmunotherapyGraft Versus Host DiseaseNeoplasm /Cancer ImmunologyBone Marrow TransplantationFlow CytometryHuman Therapy EvaluationHuman SubjectClinical Trial Phase ILeukemiaCyclophosphamidePatient Oriented ResearchArtificial ImmunosuppressionHomologous TransplantationCytotoxicityCytotoxic T LymphocyteDisease /Disorder ModelEnzyme Linked Immunosorbent AssayColony Stimulating FactorGenetically Modified AnimalsClinical TrialsHematopoietic Stem CellsTumor AntigensClinical ResearchCellular Immunity
Grant awards (6)
Clinical Trials in Graft versus Host Disease$144,583
K24 · FY2005 · CA
Clinical Trials in Graft versus Host Disease$144,583
K24 · FY2004 · CA
Clinical Trials in Graft versus Host Disease$144,583
K24 · FY2003 · CA
Clinical Trials in Graft versus Host Disease$144,583
K24 · FY2002 · CA
Clinical Trials in Graft versus Host Disease$144,583
K24 · FY2001 · CA
TUMOR VACCINES$225,914
P01 · FY2000 · CA